METTL3 and hepatocellular carcinoma: In clinical samples of HCC samples and HCC cells, METTL3 and IGF2BP2 have been shown to induce the m6A modification of WW domain‐containing protein 2 (WWP2), thereby upregulating WWP2 expression, activating AKT signaling, and enhancing glycolysis and doxorubicin resistance.362